Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Aethlon Medical (AEMD) EBITDA (2016 - 2025)

Aethlon Medical filings provide 15 years of EBITDA readings, the most recent being -$2.0 million for Q1 2025.

  • On a quarterly basis, EBITDA rose 19.39% to -$2.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was -$9.3 million, a 26.07% increase, with the full-year FY2025 number at -$13.4 million, down 9.74% from a year prior.
  • EBITDA hit -$2.0 million in Q1 2025 for Aethlon Medical, down from -$1.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.8 million in Q4 2024 to a low of -$3.8 million in Q1 2022.
  • Median EBITDA over the past 5 years was -$2.6 million (2024), compared with a mean of -$2.7 million.
  • Biggest five-year swings in EBITDA: plummeted 82.46% in 2022 and later soared 49.13% in 2024.
  • Aethlon Medical's EBITDA stood at -$2.5 million in 2021, then fell by 12.73% to -$2.8 million in 2022, then dropped by 25.17% to -$3.6 million in 2023, then soared by 49.13% to -$1.8 million in 2024, then fell by 10.43% to -$2.0 million in 2025.
  • The last three reported values for EBITDA were -$2.0 million (Q1 2025), -$1.8 million (Q4 2024), and -$2.9 million (Q3 2024) per Business Quant data.